Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 3 for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon.
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: 0 warning letters, 3 recalls, 0 approval records, 0 Form 483s.
Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.
Side by side
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Warning letters0
Philips North America — Warning letters0
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Recalls3
Philips North America — Recalls355
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Approval records0
Philips North America — Approval records0
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Form 483s0
Philips North America — Form 483s0
Timeline
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Most recent FDA action: February 1, 2023
Full history →Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"Glaxosmithkline Consumer Healthcare Holdings DBA Haleon vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed July 17, 2026. https://argushq.ai/compare/glaxosmithkline-consumer-healthcare-holdings-dba-haleon-vs-philips-north-america
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗